What we’re reading, October 24, 2016: Cigna makes it easier for clinicians to prescribe drugs to treat opioid addiction; some hospitals move to eliminate sugary drinks from their campuses; and a researcher at the National Cancer Institute was months late to notify authorities of 2 deaths in the clinical trial he oversaw.
Cigna has eased pre-authorization requirements for prescribing buprenorphine, which is used to treat opioid addiction. Previously, physicians were required to submit a prior approval form that asked several questions about the patient, sometimes waiting days for coverage approval. The move initially came as a result of a settlement between Cigna and New York State Attorney General Eric Schneiderman; Cigna then decided to amend the requirements nationwide.
Increasing numbers of hospitals are removing sugary drinks from their cafeterias and vending machines in an attempt to encourage healthier choices, but not everyone agrees on the practicality of the bans. Several hospital workers interviewed by STAT News felt that patients and visitors should have the right to decide what they want to drink. Critics of the bans also questioned the decision to leave diet sodas available, since some research says artificial sweeteners can be harmful, as well.
A researcher at the National Cancer Institute waited several months to notify authorities of 2 subjects who died during his clinical trial. Two patients with lymphoma participating in a trial of ibrunitib died of infections in May and December 2015, but the principal investigator did not file an “unanticipated problem” report until May of this year. The National Institutes of Health plans to provide training sessions for other researchers and audit more clinical trials in an effort to prevent future lapses in reporting.
NK Cell Therapy SNK01 Improves Cognitive Function in Alzheimer Disease for up to 11 Weeks
December 3rd 2023Among 10 patients evaluated, compared with their baseline at 1 week after receiving their final dose in the trial, 30% demonstrated clinical improvement on the Alzheimer’s disease composite score.
Read More
Consumers should not eat precut cantaloupe if they do not know the source, as the number of illnesses and recalls tied to a deadly salmonella outbreak grows; the White House and the Department of Education urged schools to take proactive steps to prevent youth drug use; a study published this week found a high prevalence of arrhythmia in patients with long COVID.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
Bimekizumab-bkzx, the Newest Psoriasis Treatment, Is Now Available
November 30th 2023Bimekizumab-bkzx (Bimzelx) is the first dual interleukin 17A (IL-17A) and interleukin 17F (IL-17F) inhibitor to treat moderate-to-severe plaque psoriasis. It launches with a list price of $7200 per syringe.
Read More